Nkarta, Inc. is a pharmaceutical company in the United States, specializing in developing engineered natural killer (NK) cells to combat cancer and autoimmune diseases. By harnessing the power of NK cells, the company aims to kill abnormal cells and create specific and long-lasting immune responses. With a focus on environment, sustainability, and governance (ESG), Nkarta utilizes innovative cell engineering technologies to produce an ample supply of NK cells, enhance target recognition, and improve persistency for effective cancer treatment. Headquartered in South San Francisco, California, Nkarta has a medium risk rating score of 27.9.